UBS Group
FSTX

UBS Group’s F-star Therapeutics, Inc. Common Stock FSTX Stock Holding History

UBS Group’s Portfolio FSTX Stock Details FSTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-2,224
Closed -$14K – 11458
2022
Q2 		$14K Buy
2,224
+2,174
+4,348% +$7.32K ﹤0.01% 7454
2022
Q1 		$0 Sell
50
-189
-79% -$698 ﹤0.01% 11318
2021
Q4 		$1K Sell
239
-271
-53% -$1.63K ﹤0.01% 10128
2021
Q3 		$3K Sell
510
-453
-47% -$3.11K ﹤0.01% 8890
2021
Q2 		$8K Buy
963
+189
+24% +$1.61K ﹤0.01% 8279
2021
Q1 		$9K Buy
774
+575
+289% +$5.58K ﹤0.01% 8038
2020
Q4 		$1K Sell
199
-362
-65% -$2.37K ﹤0.01% 8288
2020
Q3 		$3K Buy
561
+436
+349% +$2.61K ﹤0.01% 7594
2020
Q2 		$1K Sell
125
-1,073
-90% -$6.21K ﹤0.01% 7841
2020
Q1 		$4K Buy
1,198
+1,073
+858% +$5.55K ﹤0.01% 7434
2019
Q4 		$1K Sell
125
-465
-79% -$5.91K ﹤0.01% 8012
2019
Q3 		$8K Sell
590
-596
-50% -$9.82K ﹤0.01% 7304
2019
Q2 		$17K Buy
1,186
+547
+86% +$14.7K ﹤0.01% 6738
2019
Q1 		$27K Sell
639
-1,377
-68% -$58K ﹤0.01% 6045
2018
Q4 		$84K Buy
2,016
+315
+19% +$14.2K ﹤0.01% 5686
2018
Q3 		$82K Buy
1,701
+977
+135% +$48.9K ﹤0.01% 5757
2018
Q2 		$34K Buy
724
+200
+38% +$11.1K ﹤0.01% 6298
2018
Q1 		$33K Buy
524
+124
+31% +$6.54K ﹤0.01% 6024
2017
Q4 		$22K Sell
400
-100
-20% -$5.95K ﹤0.01% 6493
2017
Q3 		$34K Sell
500
-128
-20% -$7.33K ﹤0.01% 6080
2017
Q2 		$34K Buy
628
+46
+8% +$2.13K ﹤0.01% 5938
2017
Q1 		$21K Buy
+582
New +$20K ﹤0.01% 6114
2016
Q3 		– Sell
-94
Closed -$4K – 8026
2016
Q2 		$4K Buy
+94
New +$4.02K ﹤0.01% 7259

Other funds holding FSTX

RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
AVA
Atlas Venture Advisors Boston, Massachusetts $143M AUM 25.68% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DMKJ
David M. Knott Jr $168M AUM 60.36% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

UBS Group's FSTX Position: Q3 2022 in Review

UBS Group sold out of F-star Therapeutics, Inc. Common Stock (FSTX) in Q3 2022, closing a stake of 2,224 shares — an estimated $14K sold.

UBS Group first reported a position in FSTX in Q2 2016 and held it in 23 quarters. The position peaked at $84K in Q4 2018. 54 funds tracked by Wall St. Rank hold FSTX as of Q3 2022.

  • UBS Group reported no remaining F-star Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • UBS Group sold 2,224 F-star Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $14K.
  • UBS Group first reported a position in F-star Therapeutics, Inc. Common Stock in Q2 2016 and held it in 23 quarters.
  • UBS Group's F-star Therapeutics, Inc. Common Stock position peaked at $84K in Q4 2018.
  • 54 funds tracked by Wall St. Rank held F-star Therapeutics, Inc. Common Stock as of Q3 2022.

Based on UBS Group's 13F filing for Q3 2022, filed 10 Nov 2022.